Is health economics useful in cancer?

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 1, 1999, Pages 25-33

  Williams, Christopher J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTACID AGENT; ANTI ACNE AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; CORTICOSTEROID; CYTOSTATIC AGENT; ELECTROLYTE; LAXATIVE; MUSCLE RELAXANT AGENT; OMEPRAZOLE; PACLITAXEL; SEX HORMONE;

CANCER; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; LUNG NON SMALL CELL CANCER; METASTASIS; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; UNITED KINGDOM;

EID: 0033051938     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00037-7     Document Type: Article

References (28)

1. Backhouse M.E., Backhouse R.J., Edey S.A. Economic evaluation bibliography. Health Econ. 1:1992;1-235.
2. Elixhauser A. Health care cost-benefit and cost-effectiveness analysis (CBA/CEA). From 1979 to 1990: a bibliography. Med Care 1993;31(suppl), JS:1-149.
3. Adams M.E., McCall N.T., Gray D.T., Orza M.J., Chalmers T.C. Economic analysis in randomized controlled trials. Med. Care. 30:1992;231-243.
4. Department of Clinical Epidemiology and Biostatistics, McMaster Health Sciences Center. How to read journals: VII: to understand an economic evaluation (Part A). Can Med Assoc J 1984;130:1428-34.
5. Drummond M.F., Torrance G., Mason J. Cost-effectiveness league tables: more harm than good? Soc. Sci. Med. 37:1993;26-36.
6. Drummond M. Output measurement for resource allocation decisions in health care. McGuire A., Fenn P., Mayhew K. Providing Health Care: The Economics of Alternative Systems of Finance and Delivery. 1991;99-119 Oxford University Press, Oxford.
7. Torrance G.W. Utility approach to measuring health-related quality of life. J. Chron. Dis. 40:1987;593-600.
8. Goddard M., Drummond M. The economic evaluation of cancer treatments and programmes. Eur. J. Cancer. 27:1991;1191-1196.
9. Drummond M.F., Brandt A., Luce B., Rovira J. Standardising methodologies for economic evaluation in health care. Int. J. Technol. Assess. Health Care. 9:1993;26-36.
10. Collins R., Peto R., Gray R., Parrish S. Large scale randomised evidence: trials and overviews. Maynard A, Chalmers I Non-Random Reflections on Health Services Research. 1997;195-230 Br Med J, London.
11. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-908.
12. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.
13. Mulrow C The medical review article: state of the art. Ann. Intern. Med. 106:1987;485-488.
14. Bramwell V, Williams C. Journal of clinical oncology (JCO): how systematic are reviews? Proceedings Amer Soc Clin Oncol 1996;15:325 (abstract).
15. Cochrane AL. Effectiveness and efficiency: random reflections on health services. London, Nuffield Provincial Hospitals Trust, 1972.
16. Lau J., Antman E.M., Jimeneq-Silva J., Kupelnick B., Mosteller F., Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. New Engl. J. Med. 327:1992;248-254.
17. Williams C., Coyle D., Gray A., Hutton J., Jefferson T., Karlsson G., Kesteloot K., Uyl-de Groot C., Wait S. European School of Oncology Advisory Report to the Commission of the European Communities for the Europe Against Cancer Programme: Cost-effectiveness in cancer care. Eur. J. Cancer. 31:1995;1410-1424.
18. Green J.A. Fair and effective resource allocation in cancer care: uncharted territory? Health Care Anal. 4:1996;19-28.
19. Williams C. Allocation of scarce resources: the need for critical analysis. Health Care Anal. 4:1996;28-34.
20. Cribb A. Resource allocation and social meaning. Health Care Anal. 4:1996;34-37.
21. Bretcher B. How should we think about resource allocation? Health Care Anal. 4:1996;37-40.
22. Evans M. Treatment now or future research? Health Care Anal. 4:1996;40-44.
23. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Annals Internal Med 1995;122:61-70.
24. Evans R.G. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Annals Internal Med. 123:1995;59-60.
25. Rigby K., Silagy C., Crockett A. Health economics reviews: are they compiled systematically? Int. J. Technol. Assess. Health Care. 12:1996;450-459.
26. Neymark N. Critical reviews of economic analyses in order to make health care decisions for cancer. Annals Oncol, (in press).
27. Sheldon T.A. Problems of using modelling in the economic evaluation of health care. Health Econ. 5:1996;1-11.
28. Maynard A., Sheldon T.A. Health economics: has it fulfilled its potential? Maynard A., Chalmers I. Non-Random Reflections on Health Services Research. 1997;49-165 Br Med J, London.